Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocardia Inc (NQ: BCDA )

2.060 +0.020 (+0.98%)
Streaming Delayed Price Updated: 3:47 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biocardia Inc

< Previous 1 2 3 Next >
BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study
 
Via Benzinga
$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
BioCardia's Return On Capital Employed Insights
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
From BioCardia, Inc.
Via Business Wire
BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years
 
Via Benzinga
Recap: BioCardia Q2 Earnings
  BioCardia (NASDAQ:BCDA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022
Upgrades 
Via Benzinga
Earnings Preview For BioCardia
BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump
 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BioCardia Earnings Preview
  BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will... 
Via Benzinga
Executives Buy Around $4M Of 5 Penny Stocks
US stock futures traded slightly lower this morning on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
Recap: BioCardia Q1 Earnings
BioCardia (NASDAQ:BCDA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings BioCardia beat estimated earnings by... 
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview For BioCardia
BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million. 
Via Benzinga
Follow the Insiders and Buy the Dip in These 3 Stocks
These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
Benzinga's Daily Brief On Trending Tickers For April 12, 2022: Veru, Kohl's Corporation, BioCardia, And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Looking Into BioCardia's Return On Capital Employed
Benzinga Pro data, BioCardia (NASDAQ:BCDA) reported Q4 sales of $79.00 thousand. Earnings fell to a loss of $3.46 million, resulting in a 27.9% decrease from last quarter. 
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Outlook For BioCardia
BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will... 
Via Benzinga
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.